Reverse DCF
What growth rate is priced into Heart Test Laboratories Inc. Common Stock (HSCS)?
At the current market price of $2.28, a reverse DCF implies Heart Test Laboratories Inc. Common Stock (HSCS) must grow revenue about 13.3% per year for the next decade (21.2% in year one) to be worth what it trades for — holding margins, taxes, reinvestment, and the discount rate fixed at the model's baseline assumptions.
Market price
$2.28
Implied growth (yr 1)
21.2%
Implied 10-yr CAGR
13.3%
Heart Test Laboratories Inc. Common Stock (HSCS) reverse DCF FAQ
What revenue growth rate is priced into Heart Test Laboratories Inc. Common Stock (HSCS)?
At the current market price of $2.28, a reverse DCF implies Heart Test Laboratories Inc. Common Stock's revenue must grow about 13.3% per year for the next ten years (starting at 21.2% in year one) to justify the price — holding margins, taxes, reinvestment, and the discount rate at the model's baseline assumptions.
What is a reverse DCF?
A regular DCF turns growth assumptions into a fair value. A reverse DCF inverts that: it holds every other assumption fixed and solves for the single revenue-growth path that makes intrinsic value equal the current market price. The result is the growth the market is already paying for — a hurdle you can judge the business against.
How this HSCS implied growth is solved
The engine takes the same 10-year DCF used for the Heart Test Laboratories Inc. Common Stock fair-value estimate — margins converging to Damodaran industry benchmarks, year-by-year WACC, a reinvestment rate tied to sales-to-capital efficiency — and inverts it: instead of projecting growth to get a value, it bisects on the starting revenue-growth rate, re-running the valuation until intrinsic value matches the market price. The implied path follows the same moat-scored convergence toward the 2% terminal growth rate that the forward model uses.
The interactive version lets you change what is held fixed — margins, convergence timing, industry benchmarks — and overlays the market-implied growth path on your own editable forecast, so you can see exactly where your expectations and the market's diverge.
The implied growth re-solves when Heart Test Laboratories Inc. Common Stock files a new quarterly or annual report. For educational/informational purposes only — not investment advice. Last solved 2026-07-24.